Silibinin Alleviates Muscle Atrophy Caused by Oxidative Stress Induced by Cisplatin through ERK/FoxO and JNK/FoxO Pathways

Figure 1

SLI alleviated the weight loss of the body, food intake, muscle, epididymal adipose, liver, kidney, spleen, lung, and heart and weakened the forelimb grip strength of tumor-bearing mice after DDP treatment and did not affect the antitumor activity of DDP. (a) 5-week-old C57BL/6 mice were treated with DDP (4 mg/kg/2 d, i.p.) and given high and low doses of SLI treatment (80/40 mg/kg/d, p.o.) simultaneously; the treatment lasted for 8 days. (b) The weight of the mice was measured on day 1 and days 6–15. The change in body weight was relative to the first administration (day 6 of tumor bearing). Data are shown as , ; , versus group . (c) Total daily food intake of mice in each group. Data are shown as an individual values, ; versus group . (d) Tumor weight was measured after the mice were euthanized, and grip strength of the forelimbs was measured before the mice were sacrificed. Data are shown as , ; , , versus group . (e) After the mouse was euthanized, the GA muscle, TA muscle, epididymis adipose, liver, kidney, spleen, lung, and heart were removed and weighed. Data are shown as , ; , , versus group . (f) Comparison of leg muscles and epididymal adipose of typical mice in each group, from left to right, LLC, , (L), (H), and NC groups, respectively.

(a)

(b)

(c)

(d)

(e)

(f)